NCT02682407: A trial that was reported late by Omeros Corporation
This trial has reported, although it was 1176 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02682407 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 29, 2016 |
| Completion date | Dec. 31, 2020 |
| Required reporting date | Dec. 31, 2021, midnight |
| Actual reporting date | March 21, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1176 |